News and insights

Drug Quality, Testing and Pharmaceutical Supply-Chain Compliance

Laboratory worker handling samples with test tubes.
Photo by MART PRODUCTION via Pexels. Free Pexels image: https://www.pexels.com/photo/drugs-substance-testing-in-a-laboratory-7230411/

Published: November 9, 2026

Two CDSCO public notices dated October 27, 2026 draw attention to testing of raw materials and finished formulations and to digital monitoring of high-risk solvent supply chains. Together, these topics illustrate why pharmaceutical quality depends on controls at both the product-testing and sourcing stages.

Testing and records

Testing helps establish whether materials and finished products meet their applicable specifications. Clear records connect a test result to the material or product batch, the test performed and the responsible quality process. Vendor qualification and traceable purchasing records also help organisations assess the sources of inputs they use.

Visibility across solvent supply chains

Digital monitoring can support more consistent visibility into the movement of designated high-risk solvents. In practice, supply-chain controls should make it possible to review relevant batch, quantity, supplier and transaction information against applicable rules and official directions.

The notices are regulatory information for the sector. This general summary does not provide legal advice and does not mean that GOSIX PHARMACEUTICALS PRIVATE LIMITED holds a licence, certification or regulatory approval.

Source: Central Drugs Standard Control Organisation, Public Notices dated October 27, 2026. Read Original Source.